论文部分内容阅读
Bortezomib showed impressive results in the treatment of patients with multiple myeloma.However, the role of bortezomib in stem cell collection as a mobilization regimen is unknown.We retrospectively analyzed the effect of bortezomib as a mobilization regimen for 13 multiple myeloma patients who had undergone autologous stem cell transplantation.The stem cells were mobilized with combined chemotherapy and bortezomib plus granulocyte-colony stimulating factor (G-CSF) for 4 patients (group A), and the other 9 patients were mobilized with combined chemotherapy plus G-CSF (group B).The collected mononuclear cells were 8.02 × 108/kg and 8.19 × 108/kg for groups A and B, respectively (p>0.05).The collection of CD34+ cells with two cycles was poor for all patients in group A but only two patients in group B.The collected CD34+ cells were 1.42 ×106/kg and 6.12 ×106/kg for groups A and B, respectively (p<0.05).All patients experienced a stable engraftment.The time of engraftment was 11.00 days in group A and 11.33 (p>0.05) for white blood cells and 15.25 days in group A and 12.78 days in group B for platelet engraftment (p>0.05).The use of bortezomib as a mobilization regimen for patients with multiple myeloma is not beneficial.